
    the recently feasibility study shows that the number of patients is insufficient in the centers
  
['autistic disorder']
['bumetanide', 'placebo']

        Inclusion Criteria:

          -  Children and teenager from age 5 to age 17, with a diagnosis of typical autism or
             Asperger syndrome according to the criteria of diagnosis of the WHO's classification
             (CIM-10),

          -  With a known etiology,

          -  Patients for whom the CARS results are strictly Superior or equal to 30,

          -  Of whom the parents have given their free, informed and written consent,

          -  Affiliated or beneficiary of the French social security.

        Exclusion Criteria:

          -  Patients under treatment by inlet diuretic either at the time of the study or before,

          -  Patients with electrolytic disorders,

          -  Patients with a known hypersensitivity to sulfa drugs,

          -  Patients with a hepatic or renal failure,

          -  Patients with an epilepsy not controlled by a treatment (comitial crisis in the past 6
             month at the time the trial starts despite a treatment),

          -  Patients under treatment by psychotropic exception made of the melatonin,

          -  Allergy to the bumetanide or one of its excipients,

          -  Patient under a treatment by lithium, diphemanil, erythromycin IV, halofantrine,
             pentamidine, sultopride, vincamine, aminoglycoside,

          -  Pregnant and lactating women.

        Secondary exclusion criteria:

          -  QT prolongation noticed on the ECG at Day0,

          -  Anomaly on the biological check up (Day 0) made before including the patient that
             would contraindicated the prescription of bumetanide,

          -  Patients for whom the CARS results are strictly inferior to 30.
      